Last reviewed · How we verify
TRL1068, a human monoclonal antibody
TRL1068, a human monoclonal antibody is a Small molecule drug developed by Trellis Bioscience LLC. It is currently in Phase 1 development.
At a glance
| Generic name | TRL1068, a human monoclonal antibody |
|---|---|
| Sponsor | Trellis Bioscience LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection (PHASE2)
- Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections (PHASE1)
- Study to Evaluate Safety and Activity of TRL1068 in Chronic Rhinosinusitis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRL1068, a human monoclonal antibody CI brief — competitive landscape report
- TRL1068, a human monoclonal antibody updates RSS · CI watch RSS
- Trellis Bioscience LLC portfolio CI
Frequently asked questions about TRL1068, a human monoclonal antibody
What is TRL1068, a human monoclonal antibody?
TRL1068, a human monoclonal antibody is a Small molecule drug developed by Trellis Bioscience LLC.
Who makes TRL1068, a human monoclonal antibody?
TRL1068, a human monoclonal antibody is developed by Trellis Bioscience LLC (see full Trellis Bioscience LLC pipeline at /company/trellis-bioscience-llc).
What development phase is TRL1068, a human monoclonal antibody in?
TRL1068, a human monoclonal antibody is in Phase 1.